EGFR and neoplasm: Although there is conflicting data regarding the prognostic role of AR expression in endocrine treatment response, an in vitro effect of AR expression on tamoxifen resistance has been observed, potentially mediated through activation of EGFR signalling pathways and the adaptation of the tumour cells from oestrogen to androgen dependent has been demonstrated as another mechanism of resistance to ER targeted therapies [13, 43, 44].